Bayer Buys Cancer-Fighting Antibody Rights For $426M
Under the agreement, the two companies will develop a new BiTE antibody for the treatment of solid tumors in cancer patients. BiTE antibodies are used to direct the body's cytotoxic, or cell-destroying, T cells, to attack tumors, creating what Micromet said is a new therapeutic approach to treating cancer.
Bayer and Micromet first entered into an...
To view the full article, register now.